At its Q3 2026 results briefing, Botuo Biotech said it will retain POCT rapid
diagnostics as its core business, expand its product matrix, accelerate domestic
and overseas registrations/certifications, and advance a microfluidic
fluorescent detection platform and high-end microfluidic chip reagent
development to strengthen POCT competitiveness. The company said it is also
deploying an industrial investment platform—via equity stakes, M&A and
participation in industry funds—to explore frontier medical areas including
brain–computer interfaces (BCI) and AI-driven healthcare, aiming to open
long-term potential growth avenues.